Status:
COMPLETED
Efficacy of Dipotassium Glycyrrhizinate Emollients in the Maintenance Treatment of Adult Atopic Dermatitis
Lead Sponsor:
The Affiliated Hospital of Xuzhou Medical University
Conditions:
Adult Atopic Dermatitis
Eligibility:
All Genders
17-64 years
Phase:
NA
Brief Summary
To investigate whether emollients containing dipotassium glycyrrhizinate have a sustained improvement in the clinical severity of mild to moderate atopic dermatitis in adult.
Detailed Description
Atopic dermatitis (atopic eczema, AD) is a common skin inflammatory disease, dry skin and itchy skin is a significant symptom of most AD, often accompany patients for life, seriously affecting the phy...
Eligibility Criteria
Inclusion
- Meet the Williams diagnostic criteria
- SCORAD scores \< 50 points, classified according to the severity levels of SCORAD scores, where scores of 0-25 are categorized as mild, and scores of 26-50 are categorized as moderate
- No gender limit, age between 18-65 years old.
Exclusion
- Acute disease with erosion, exudation, secondary infection
- There are currently other active inflammatory skin diseases
- Antihistamine was used within 2 weeks prior to enrollment
- Patients treated with emollients and receiving topical drugs (such as glucocorticoids and calcineurin inhibitors) within 1 week before enrollment
- Patients have used phototherapy, systemic corticosteroids, immunosuppressants (such as cyclosporine, azathioprine, or immunoglobulin, etc.) within 4 weeks before enrollment
- The systematic withdrawal time of biological agents or JAK inhibitor (dupilumab, omalizumab, et al) was less than 12 weeks
- Malignant tumors, chronic systemic diseases (such as diabetes mellitus, hypothyroidism), or other acute and chronic infections
- Those known to be allergic to the ingredients of emollient or Hydrocortisone cream
- Patients who have attended or are attending other clinical investigators within three months
- Patients judged unsuitable by the investigator to participate in this study.
Key Trial Info
Start Date :
October 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06565117
Start Date
October 1 2021
End Date
February 1 2023
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China, 221002